GeneQuantum is a recognized pioneer in bioconjugate drug discovery, validated by late-stage assets and strategic partnerships. Built on its world-leading site-specific conjugation technology, the company has created the industry’s first high-throughput ADC screening platform. This enables rapid, systematic optimization of antibody, linker, and payload combinations, generating first and best-in-class ADCs with tuned PK, DAR, and therapeutic index, as well as novel dual payloads and multi-specific antibody formats. GeneQuantum aims to realize the broad global value of its assets through strategic partnerships, including co-development, licensing, and NewCos.
www.genequantum.com
